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• Survival was compared in terms of initial dose of pegylated liposomal doxorubicin (PLD) with propensity score analysis.
• After matching with propensity score, the survival difference was not signiﬁcant (50 vs. 40 mg/m2 PLD).
• Incidence and severity of palmar-plantar erythrodysesthesia and stomatitis were signiﬁcantly lower with 40 mg/m2 of PLD.☆ Sources of support: the DOX2L study was cond
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Available online 6 September 2016Background. In clinical practice, 40 mg/m2 of pegylated liposomal doxorubicin (PLD40) has been used as an
initial dosage for treating recurrent epithelial ovarian cancer (OC) instead of the recommended dose of 50 mg/
m2 (PLD50). However, no robust evidence is available to support the use of PLD40. This post-hoc study aimed
to compare the efﬁcacy and safety of initial PLD dosages in propensity score (P-score)-matched dataset.
Methods. The data source was a PLD postmarketing surveillance dataset (n= 2189) conducted in Japan. Eli-
gibility criteria for the present study were as follows: recurrent OC, history of chemotherapy, and treatmentwith
PLD monotherapy at a dosage between 35.5 and 54.4 mg/m2. Overall survival (OS) was compared between
PLD50- and PLD40-treated groups using the log-rank test. Incidences of palmar-plantar erythrodysesthesia
(PPE) and stomatitis were also compared between the groups.
Results. Overall, 503 matched pairs were generated using P-score analysis. The median survival time with
PLD50 and PLD40 was 383 and 350 days, respectively, with a hazard ratio of 1.10 (95% conﬁdence interval,
0.98–1.26; p= 0.211), although the difference was not statistically signiﬁcant in the P-score-matched dataset.
However, the incidence and severity of PPE and stomatitis were signiﬁcantly lower with PLD40.
Conclusions. Our study showed that the efﬁcacy of PLD did not differ based on initial dosages, but the risk of
adverse events was reducedwith PLD40. Considering the balance between patient beneﬁts and risks, our results
support the use of PLD40 in clinical practice.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under1. Introduction
Epithelial ovarian cancer (OC) is one of the leading causes of cancer
death worldwide; it is the ﬁfth most common cause of cancer death
among females, and accounts for an estimated 152,000 deaths per
year [1]. Surgery followed by paclitaxel with carboplatin is the recom-
mended standard of care for newly diagnosed OC, however, very few
percent of patients are failing during treatment and unfortunately the
majority recurring after a median short of 2 years [2]. This makes treat-
ment for recurrence a major issue in management. For recurrent OC,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tivity [3]. Pegylated liposomal doxorubicin (PLD) has indication for re-
current OC, and is globally recommended for platinum-resistant
recurrent OC. The approved dose of PLD is 50 mg/m2/day every
4 weeks, this dose was selected based on two phase I studies [4] and
used registration studies conducted to gain regulatory approval in sev-
eral countries [5,6], actually in some randomized trials for registration
purpose of newdrugs for recurrent OC, PLD 50mg/m2 has been selected
as control arm [7,8]. However, the initial dose in clinical practice re-
mains uncertain due to the occurrence of dose-limiting toxicities, in-
cluding palmar-plantar erythrodysesthesia (PPE) and stomatitis.
Markman et al. [9] ﬁrstly reported an exploratory study with a small
sample size (n = 49) on the clinical utility of a lower dose of PLD
(40 mg/m2) in order to achieve improvement of tolerability. Then,
two retrospective analyses have reported that there was no difference
in progression-free survival (PFS) or overall survival (OS) between 40-
and 50-mg PLD dose groups, and the 40 mg/m2 group appeared to
show better tolerability [10,11]. Because these studies were conducted
with small sample sizes, from limited hospitals and patient back-
grounds, the results may be biased and not optimally adjusted. Al-
though these efforts were considerably informative at the early stages
of clinical implementation of PLD, the robustness and statistical power
of the studies were limited. Dose rate of 10 mg/m2/week under many
circumstances may be a more relevant way to look at the data and
this dose intensity of PLD is the generally accepted in the oncology com-
munity [12]. In light of the aforementioned background, this dose was
selected for treatment arm in some randomized controlled trials [13,
14], also the European panel of experts and the latest Japanese ovarian
cancer guidelines recommended the use of 40 mg/m2 of PLD [15,16].
However, there is still no robust evidence to support the dose selection
of PLD 40 mg/m2.
Propensity score (P-score) analysis is a recently developed statistical
method that can estimate treatment effects based on observational data.
P-score analysis provides a balancewith regard to subjects' background
in treated and control groups through calculation of a P-score using
baseline covariates that are considered to affect selection bias [17].
Studies utilizing P-score analysis have become increasingly prevalent
in the literature [18–20].
In the present study, we retrospectively evaluated the risk–bene-
ﬁt balance between initial dosages of PLD 40 mg/m2 and 50 mg/m2
using P-score analysis in a large postmarketing real-world dataset
from Japan.2. Patients and methods
2.1. Data source and study population
This study was a post-hoc analysis that used an existing dataset
from DOX2L which was a prospective, observational (non-interven-
tional) study for the evaluation of the safety and efﬁcacy of PLD in re-
current OC. From April 2009 to June 2012, a total of 2189 consecutive
patients were centrally registered from 536 hospitals located in
Japan; survival was followed up to 2 years. DOX2L was conducted
under the Japanese Pharmaceutical Affairs Act and regulated by the
Good Post-Marketing Study Practice. The protocol was reviewed
and approved by the Ministry of Health, Labour and Welfare and
the Pharmaceuticals and Medical Devices Agency in Japan. The orig-
inal results have been published [21]. Eligibility criteria for the pres-
ent study were as follows: (1) epithelial OC, (2) history of one or
more anti-cancer chemotherapies for OC, (3) treatment with PLD
monotherapy, and (4) treatment with initial PLD dosage between
35.5 and 54.4 mg/m2. Because we considered some physicians use
a 35 mg/m2 of PLD [11], therefore, we select the lower dose to ex-
clude target dose 35 mg/m2. The upper dose was selected to exclude
over dose.2.2. Available parameters
The original study collected age, body weight, height, Eastern Coop-
erativeOncologyGroup performance status (ECOG-PS), histology, Inter-
national Federation of Gynecology and Obstetrics (FIGO) staging, and
treatment history for OC as baseline characteristics. PLDdosage, adverse
events, laboratory examination values relating to adverse events were
collected. Anti-tumor response according to the new response evalua-
tion criteria in solid tumors (RECIST) guidelines [22] were collected
only from applicable or available patients. Treatment-free interval
(TFI), deﬁned as the duration from the last chemotherapy dosing to
the ﬁrst dose of PLD, was calculated using prior chemotherapy informa-
tion. OS was deﬁned as the duration from the ﬁrst dosing of PLD to the
last follow-up date. In addition, PPE and stomatitis were intensively in-
vestigated in the study, and their development and severity were man-
datory reporting events in the clinical report form. Serious adverse
events were deﬁned by the following criteria: adverse events that (1)
resulted in death, (2) were life-threatening, (3) resulted in a persistent
or signiﬁcant disability/incapacity, (4) required either inpatient hospi-
talization or prolongation of hospitalization, (5) caused other important
medical events, based upon appropriatemedical judgment as towheth-
er patient health was at risk and intervention was required to prevent
an outcome mentioned above in numbers 1 to 4, and (6) resulted in a
congenital anomaly/birth defect.2.3. Comparative group generation by propensity score analysis
Caseswere deﬁned as patients treatedwith an initial dose of PLD be-
tween 35.5 and 44.4mg/m2 (PLD40), dose were rounded to the nearest
10 mg/m2, while controls were deﬁned as patients treated with a dose
between 44.5 and 54.4 mg/m2 (PLD50). Primarily, a full dataset of eligi-
ble patients was analyzed. Patient characteristics were compared ac-
cording to the dose groups; subsequently, treatment exposure;
efﬁcacy including OS and disease control rate (DCR), deﬁned as either
complete response or partial response or stable disease [22]; and inci-
dences and severity of PPE and stomatitis were compared between
the dose groups.
Baseline variableswhichmet either of the following criteriawere se-
lected for P-score estimation (1) variables shown to be signiﬁcantly as-
sociatedwith prognosis of survival in other studies andwhich showed a
signiﬁcant difference between the dose groups in the full dataset analy-
sis and (2) variables which showed a signiﬁcant difference between
dose groups in the full dataset analysis. Eight variables including patient
baseline and hospital characteristicswere selected, and a logistic regres-
sion model was used for P-score estimation. We used caliper matching
with a width of 15% of standard deviation (SD) and one-to-one
matching with non-replacement.2.4. Statistical analysis
We compared baseline characteristics, median cumulative dose of
PLD, median total cycles of PLD, OS, DCR, and incidence of PPE and sto-
matitis according to the dose groups in the pre- and post-matched
datasets.
Fisher's exact test or Chi square test was used for comparisons be-
tween individual categorical independent variables. Logistic regression
models were used for ordinal variables. For continuous variables, t test
was used. Survival analyses were performed using the Kaplan–Meier
method and two-sided log-rank test. For the P-score-matched dataset,
univariate and multivariate survival analyses were also performed
using a Cox proportional hazard model. ECOG-PS and TFI, which are
well known predictors for recurrent OC chemotherapy, were included
in the independent variables [3]. All tests were two-sided, and a
p value of b0.05 was considered signiﬁcant.
Fig. 1. Patient ﬂow diagram.
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formedusingR version 3.1.0 (A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna, Austria).
3. Results
3.1. Patient characteristics of all eligible patients
Of 2189 patients whowere registered in DOX2L, a total of 1790were
eligible for the present study, 1064 were allocated to PLD50 and 726 to
PLD40 (Fig. 1).Mean (±SD) initial PLD dosewas 49.9 (±0.5)mg/m2 for
PLD50 and 40.2 (±1.2) mg/m2 for PLD40. Patient characteristics of the
eligible patients according to dosage group are summarized in Table 1.
Eight variables, age, ECOG-PS, duration from OC diagnosis to PLD ﬁrst
dose, TFI, history of anthracycline exposure, history of platinum expo-
sure, hospital type (university hospital and cancer center vs. other hos-
pital), and region of hospital were statistically different between the
dose groups. PLD dosage divergencewas especially noticeable by region
of hospital; the maximum proportion of patients treated with PLD50
was 85.3% in Tohoku area (north-eastern part of Japan), and the mini-
mum was 26.4% in Kushu area (south-western part of Japan).
3.2. Treatment outcomes of all eligible patients
Table 1 also includes PLD exposure and DCR of all eligible patients.
The median number of treatment cycles was the same and the cumula-
tive dose was statistically higher in the PLD50 group. DCR was not sig-
niﬁcantly different. Fig. 2 shows the survival curves without any
adjustment. The median survival time was 422 days with PLD50 andTable 1
Baseline characteristics and treatment outcomes (full dataset).
PLD 50 mg (n= 1064)
Median age (range) 60 (16–85)
ECOG-PS; 0/1/2/3/4 498/339/105/30/2
Histology; Ser/Mu/En/Cl/other, unknown 630/39/130/120/145
Median days of diagnosis to PLD (range) 980 (21–8456)
Treatment-free intervala 869/130/54
Hospital type; University, Cancer Center/other 482/582
Location of hospitalb 73/111/432/121/133/9
Previous history of anthracycline exposure 9.7%
Previous history of platinum exposure 98.2%
Previous history of taxane exposure 97.6%
Median cumulative dose of PLD, mg/m2 (range) 167 (48–1050)
Median total cycles of PLD (range) 3 (1−21)
Disease control rate 56.9%
a Duration from last chemotherapy to PLD, ≤179 days/180–359 days−/≥360 days.
b Hokkaido/Tohoku/Kanto-Shinetsu/Tokai-Hokuriku/Kinki/Chugoku/Shikoku/Kyushu-Okina
mutinous; En, endometrioid; Cl, clear cell; PLD, pegylated liposomal doxorubicin.348 days with PLD40, OS was statistically different between the groups
(hazard ratio [HR], 1.24; 95% conﬁdence interval [CI], 1.10–1.40;
p b 0.001, log-rank test).
Table 2 summarizes adverse events. Both adverse events were more
frequent in PLD50.
3.3. Propensity score calculation and patient characteristics of post-
matched dataset
P-scores were calculated using the aforementioned eight baseline
variables which showed a signiﬁcantly different distribution between
the dose groups. The median P-score was 0.283 (range, 0.047–0.900)
with PLD50 and 0.549 (range, 0.064–0.905) with PLD40. Overall, 503
matched pairs were generated using P-score matching. Mean (±SD)
initial PLD dose was 49.9 (±0.5) mg/m2 for PLD50 and 40.2 (±1.3)
mg/m2 for PLD40. Table 3 summarizes the patient characteristics after
matching. No variable was signiﬁcantly different between the groups.
3.4. Treatment outcomes of matched patients
After the P-score matching, PLD exposure and DCR kept similar
trend with full dataset (Table 3). However in OS, difference was no lon-
ger signiﬁcant between the dose groups. The median survival time was
383 and 350 days with PLD50 and PLD40, respectively (Fig. 3); HR was
1.102 (95% CI, 0.976–1.245; p= 0.211, log-rank test). In the univariate
and multivariate Cox regression analysis, ECOG-PS and TFI were signif-
icantly affected in terms of survival (Supplemental Table S1).
Table 2 also shows adverse events of the matched dataset, adverse
events were still frequently observed with PLD50.PLD 40 mg (n= 726) p value
61 (22–89) 0.046
345/212/91/40/4 0.011
420/36/80/77/113 0.450
931 (17–8447) 0.807
639/50/30 b0.001
242/484 b0.001
4/42/58 29/19/132/128/190/47/19/162 b0.001
6.9% 0.039
96.1% 0.010
96.5% 0.247
135 (37.5–760) b0.001
3 (1–19) 0.194
54.9% 0.468
wa ECOG-PS, Eastern Cooperative Oncology Group performance status; Ser, serous; Mu,
Fig. 2. Overall survival of full dataset; green, PLD 50 mg/m2; blue, PLD 40 mg/m2.
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In the early stage of anti-neoplastic drug development, dose ﬁnding
of cytotoxic agents is evaluated under the concept of maximum tolerat-
ed dose (MTD) ﬁnding. For most cytotoxic agents, MTD or one lower
dose level is used as a recommended dose for subsequently conducted
exploratory and/or conﬁrmatory trials in several cases [23,24]. In the
clinical development of PLD, MTD was deﬁned as 40 to 60 mg/m2 on
an every 4 weeks schedule [4], and 50 mg/m2 was selected for subse-
quently conducted clinical trials [9,25]. In the trials, PPE and stomatitis
were recognized as dose-limiting toxicities; while PPE and stomatitis
did not directly cause life-threatening situations such as leucopenia or
thrombocytopenia, PPE might affect patients' ability to work and walk,
and stomatitis could affect food consumption if developed [26,27].
Theywere considered to inﬂuence activities of daily living (ADL) and di-
rectly degrade quality of life [28].
In the original dataset, OS was statistically different with regard to
the initial PLD dosages. However, several patient backgrounds,Table 2
ADL-related adverse events.
Full dataset
PLD 50 mg (n = 1064) PLD 40 mg (n = 726)
PPE Total 485 (45.6%) 264 (36.4%)
Serious 65 (6.1%) 26 (3.6%)
Stomatitis Total 500 (47.0%) 201 (27.7%)
Serious 72 (6.8%) 11 (1.5%)
ADL, activities of daily living; PPE, palmar-plantar erythrodysesthesia.
Table 3
Baseline characteristics and treatment outcomes (propensity-score matched dataset).
PLD 50 mg (n = 503
Median age (range) 61 (31–84)
ECOG-PS; 0/1/2/3/4 243/169/62/27/2
Histology; Ser/Mu/En/Cl/other, unknown 288/22/65/49/79
Median days of diagnosis to PLD (range) 967 (21–8456)
Treatment-free intervala 447/40/16
Hospital type; University, Cancer Center/other 173/330
Location of hospitalb 28/20/121/94/126/45
Previous history of anthracycline exposure 9.1%
Previous history of platinum exposure 97.4%
Previous history of taxane exposure 97.4%
Median cumulative dose of PLD, mg/m2 (range) 150 (48–1050)
Median total cycles of PLD (range) 3 (1–21)
Disease control rate 43.8%
a Duration from last chemotherapy to PLD, ≤179 days/180–359 days−/≥360 days.
b Hokkaido/Tohoku/Kanto-Shinetsu/Tokai-Hokuriku/Kinki/Chugoku/Shikoku/Kyushu-Okina
mutinous; En, endometrioid; Cl, clear cell; PLD, pegylated liposomal doxorubicin; SD standardincluding TFI and ECOG-PS which are well-known predictive factors
for recurrent OC, were unbalanced [29,30]. In addition, we referred
the following studies to determine the region and type of hospital for
the P-score estimation: (1) Keeler et al. reported that teaching hospitals
tend to have advantages in medical care and lower mortality rates [31],
(2)Tracey et al. reported that the HR for OCwas lower in hospitals with
a gynecologic oncology division [32], and (3) Terashima et al. reported
that OS in OC was different between hospitals in Japan [33]. Among
the matched dataset, patient characteristics and treatment outcomes,
except total PLD dose, were well balanced between the groups. Theme-
dian survival time was 383 days with PLD50 and 350 days with PLD40.
These ﬁndings are similar to previous reports of PLD in randomized tri-
als for taxane-treated platinum-resistant recurrent OC [13,34]. The
Kaplan–Meier survival curves mostly overlapped, except from 100 to
400 days, and difference in OS was no longer statistically signiﬁcant be-
tween the groups based on log-rank test and Cox regression analysis.
The incidence and severity of PPE and stomatitis showed similar
trends between the unmatched and matched datasets. In the matched
dataset, the incidence and severity of PPE was signiﬁcantly lower with
PLD40. The incidence and severity of stomatitis were also signiﬁcantly
lower with PLD40.
The pathogenesis of PPE was not well clariﬁed. Yokomichi et al. re-
ported in their non-clinical study that extravasation of doxorubicin by
long-term circulation of PLD caused reactive oxygen species through in-
teraction with Cu(II) ions in the skin and induced cell apoptosis [35].
Several clinical trials for anti-PPE prophylaxis have been conducted,
and a potentially effective prophylactic has been identiﬁed; however,
studies have still not conﬁrmed its effectiveness [36–38]. For stomatitis,
no prophylaxis has been developed as yet, and supportive oral care is
recommended before and after administration of PLD [39]. To date,
dose reduction of PLD is recognized as the only effectivemeasure for re-
lief from these toxicities. However, it should be cautioned that one
fourth of patients developed these adverse events, and serious events
were not completely eliminated even after reducing the dosage. Careful
observation by healthcare professionals and adequate communication
with patients and their families are essential to prevention andPropensity-score matched dataset
p value PLD 50 mg (n= 503) PLD 40 mg (n= 503) p value
b0.001 228 (45.3%) 188 (37.4%) 0.012
0.021 35 (7.0%) 21 (4.2%) 0.073
b0.001 242 (48.1%) 141 (28.0%) b0.001
b0.001 37 (7.3%) 4 (0.8%) b0.001
) PLD 40 mg (n = 503) p value
61 (22–89) 0.821
252/166/61/22/2 0.952
286/21/62/57/77 0.948
952 (17–7846) 0.466
443/39/21 0.725
199/304 0.103
/17/52 24/18/122/92/130/43/19/55 0.998
8.0% 0.573
95.8% 0.222
96.6% 0.579
135 (37.5–760) 0.001
3 (1–19) 0.680
44.8% 0.788
wa ECOG PS, Eastern Cooperative Oncology Group performance status; Ser, serous; Mu,
deviation.
Fig. 3. Overall survival of propensity-score matched dataset; green, PLD 50 mg/m2; blue,
PLD 40 mg/m2.
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PPE and stomatitis caused by PLD are warranted.
Since DOX2L was not designed to compare efﬁcacy and safety be-
tween PLD dosages, some limitations exist. Variables that had been re-
ported as signiﬁcant predictors of survival such as tumor burden,
existence of ascites, CA-125 level, and time to relapse [40] were not
mandatory items to be recorded in the original study; it was therefore
impossible to include these variables in the P-score analysis, and their
potential relationship to the outcomes of interest are unknown. Subse-
quent treatments were not recorded, and therefore were not able to be
investigated in this study. Furthermore, there could be unknown/un-
measured confounders that would have affected survival.
Considering that approved anti-neoplastic agents for platinum-re-
sistant OC are limited, PLD is likely to be selected as the standard of
care for OC. Our study provides evidence supporting the use of PLD40
in clinical practice. JGOG-3018, designed to compare OS between
PLD50 and PLD40 treatment in recurrentOCpatients, is ongoing. The re-
sults of the present study will be ﬁnally conﬁrmed and endorsed
through the results of this trial (Clinical trial ID: UMIN000003130).
In conclusion, the present study showed similar efﬁcacy with re-
duced ADL-limiting adverse events with PLD40 compared with PLD50.
These results support the clinical use of an initial dose of PLD40 in
terms of beneﬁt–risk balance.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2016.08.331.
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